ONLY CONNECT

© 2 0 0 9 T H E A U T H O R S J O U R N A L C O M P I L A T I O N © 2 0 0 9 B J U I N T E R N A T I O N A L 1 4 2 5 in cancer. Nat Rev Cancer 2003; 3 : 110– 6 7 Okazawa M, Shiraki T, Ninomiya H et al. Endothelin-induced apoptosis of A375 human melanoma cells. J Biol Chem 1998; 273 : 12584–92 8 Carducci MA, Padley RJ, Breul J et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebocontrolled trial. J Clin Oncol 2003; 21 : 679–89 9 Carducci MA, Saad F, Abrahamsson PA et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007; 110 : 1959–66 10 Nelson JB, Love W, Chin JL et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormonerefractory prostate cancer. Cancer 2008; 113 : 2478–87 11 Beer TM, Ryan CW. The hazards of intermediate endpoints. Cancer 2007; 110 : 1877–9 12 Dawson NA. Targeted therapy in prostate cancer – are we our own worst enemy? Cancer 2008; 113 : 2376–8 13 Growcott JW. Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054. Anticancer Drugs 2009; 20 : 83–8 14 James ND, Caty A, Borre M et al. Safety and efficacy of the specific endothelin A receptor antagonist ZD4054 in patients with hormoneresistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebocontrolled, randomized, Phase II trial. Eur Urol 2009; 55 : 1112–23 15 Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26 : 1148– 59